Pharma Mar, S.A. (BME:PHM)
Spain · Delayed Price · Currency is EUR 78.95
+1.25 (1.61%)
Aug 7, 2026, 1:40 PM CET
Pharma Mar Revenue
In the year 2025, Pharma Mar had annual revenue of 221.39M EUR, down -36.74%. Pharma Mar had revenue of 63.07M in the quarter ending December 31, 2025, a decrease of -26.77%.
Revenue (ttm)
393.38M
Revenue Growth
-3.34%
P/S Ratio
6.16
Revenue / Employee
432.96K
Employees
505
Market Cap
1.35B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 221.39M | -128.57M | -36.74% |
| Dec 31, 2024 | 349.96M | 191.81M | 121.28% |
| Dec 31, 2023 | 158.15M | -201.32M | -56.00% |
| Dec 31, 2022 | 359.47M | 129.64M | 56.41% |
| Dec 31, 2021 | 229.83M | -40.13M | -14.87% |
| Dec 31, 2020 | 269.96M | 129.26M | 91.87% |
| Dec 31, 2019 | 140.70M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Grifols | 7.42B |
| Almirall | 1.16B |
| Laboratorios Farmaceuticos Rovi | 773.05M |
| Faes Farma | 711.06M |
| Laboratorio Reig Jofre | 335.01M |
| Clínica Baviera | 320.15M |
| Prim, S.A. | 251.89M |
| Atrys Health | 144.31M |
Pharma Mar News
- 8 days ago - Pharma Mar Earnings Call Transcript: Q2 2026 - Transcripts
- 8 days ago - Pharma Mar Quarterly report: Q2 2026 - Filings
- 8 days ago - Pharma Mar Earnings release: Q2 2026 - Filings
- 7 weeks ago - Pharma Mar price target lowered to EUR 100 from EUR 120 at Chardan - TheFly
- 3 months ago - Pharma Mar Quarterly report: Q1 2026 - Filings
- 3 months ago - Pharma Mar Earnings release: Q1 2026 - Filings
- 3 months ago - Pharma Mar initiated with a Buy at BTIG - TheFly
- 4 months ago - Pharma Mar Slides: Corporate presentation - Filings